NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity

Completed

Conditions: Brain Tumors

Interventions: Drug: 2-Flourodeoxyglucose

First Posted Date: 2003-08-28

Last Posted Date: 2023-06-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 79

Registration Number: NCT00067821

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Improving Body Image in Middle Schoolers

Phase 1

Completed

Conditions: Healthy
Body Image

First Posted Date: 2003-08-27

Last Posted Date: 2010-01-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT00067652

Locations: 🇺🇸
Inflexxion, Inc., Newton, Massachusetts, United States

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

Phase 1

Completed

Conditions: Recurrent Ovarian Epithelial Cancer

Interventions: Biological: ALVAC-hB7.1
Biological: recombinant interferon gamma
Other: laboratory biomarker analysis

First Posted Date: 2003-08-25

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00004032

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Aggrenox Prevention of Access Stenosis

Phase 3

Completed

Conditions: Kidney Failure

Interventions: Drug: Aggrenox
Drug: Placebo

First Posted Date: 2003-08-13

Last Posted Date: 2017-09-19

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 649

Registration Number: NCT00067119

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 6 locations

Adjuvant Nutrition for Critically Ill Trauma Patients

Phase 1

Completed

Conditions: Trauma

First Posted Date: 2003-08-13

Last Posted Date: 2010-01-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 100

Registration Number: NCT00067132

Locations: 🇺🇸
University Medical Trauma Center/UNSOM, Las Vegas, Nevada, United States

Computer Intervention for Prevention of Weight Regain

Phase 3

Completed

Conditions: Obesity

First Posted Date: 2003-08-13

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 300

Registration Number: NCT00067145

Locations: 🇺🇸
The Miriam Hospital, Providence, Rhode Island, United States

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

Phase 2

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

Interventions: Biological: recombinant interleukin-12
Other: laboratory biomarker analysis

First Posted Date: 2003-08-13

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 105

Registration Number: NCT00003210

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

506U78 in Treating Patients With Refractory Hematologic Cancer

Phase 2

Completed

Conditions: Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Lymphoblastic Lymphoma
T-cell Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: nelarabine
Drug: methotrexate
Drug: cytarabine
Drug: therapeutic hydrocortisone

First Posted Date: 2003-08-11

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 148

Registration Number: NCT00002970

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Limited Stage Small Cell Lung Cancer

Interventions: Drug: tirapazamine
Drug: cisplatin
Drug: etoposide
Radiation: radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2003-08-07

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00066742

Locations: 🇺🇸
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Lung Cancer
Primary Peritoneal Cavity Cancer
Head and Neck Cancer
Ovarian Cancer
Cervical Cancer
Malignant Mesothelioma
Fallopian Tube Cancer
Pancreatic Cancer

First Posted Date: 2003-08-07

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00066651

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

Home Terms & Conditions Privacy Policy